In Section A, individuals will receive diverse doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. Further members might be enrolled within the discovered monotherapy dosign program. In Section B, individuals will receive oral ruxolitinib and ABBV-744 will probably be provided as "incorporate-on" therapy. In Segment C, https://clinicaleffectivenessofab80235.loginblogin.com/38983142/5-easy-facts-about-is-abbv-744-effective-for-hematologic-cancers-described